Tocqueville Asset Management’s Travere Therapeutics TVTX Stock Holding History

Tocqueville Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-25,000	Closed	-$226K	–	990
2014 Q3	$226K	Hold	25,000	–	–	﹤0.01%	792
2014 Q2	$294K	Buy	25,000 +17,500	+233%	+$237K	﹤0.01%	868
2014 Q1	$159K	Buy	+7,500	New	+$115K	﹤0.01%	845

Other funds holding TVTX

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

Tocqueville Asset Management's TVTX Position: Q4 2014 in Review

Tocqueville Asset Management sold out of Travere Therapeutics (TVTX) in Q4 2014, closing a stake of 25,000 shares — an estimated $226K sold.

Tocqueville Asset Management first reported a position in TVTX in Q1 2014 and held it in 3 quarters. The position peaked at $294K in Q2 2014. 65 funds tracked by Wall St. Rank hold TVTX as of Q4 2014.

Tocqueville Asset Management reported no remaining Travere Therapeutics position as of Q4 2014 after selling out during the quarter.
Tocqueville Asset Management sold 25,000 Travere Therapeutics shares in Q4 2014, an estimated $226K.
Tocqueville Asset Management first reported a position in Travere Therapeutics in Q1 2014 and held it in 3 quarters.
Tocqueville Asset Management's Travere Therapeutics position peaked at $294K in Q2 2014.
65 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2014.

Based on Tocqueville Asset Management's 13F filing for Q4 2014, filed 30 Jan 2015.